The argument for preventive health assessment is sometimes dismissed with the observation that prevention has not been shown to save money at the population level, because people who do not die from one disease live long enough to develop another. This is a technically accurate but morally and practically misleading framing. The question is not whether prevention makes people immortal or eliminates all future healthcare costs; it is whether preventing a heart attack at 58 is better for the individual than having one, and whether early detection of insulin resistance is better for someone's health and finances than managing the consequences of type 2 diabetes for 20 years. On both counts, the answer is unambiguously yes. The Longevity MOT is not primarily an economic argument, although the economics are compelling; it is an argument for having the information needed to make the choices that determine how well and how independently you live through your 60s, 70s, and 80s.
The Lifetime Cost of Preventable Chronic Disease
Type 2 diabetes costs the NHS approximately 10 billion pounds per year in England, representing approximately 10 percent of the total NHS budget. For an individual diagnosed at 55, the lifetime healthcare costs associated with their diabetes and its complications, including retinopathy, nephropathy, neuropathy, cardiovascular disease, and the amputations, dialysis, and other interventions associated with advanced complications, are estimated to exceed 20,000 to 40,000 pounds over the remaining decades of their life. This figure excludes the cost to the individual in lost productivity, reduced quality of life, and the care requirements produced by diabetes-related disability. Preventing the development of type 2 diabetes through early identification and management of insulin resistance costs a fraction of this: the Diabetes Prevention Programme in the UK delivers a structured lifestyle intervention at a cost per participant that is recovered in reduced NHS expenditure within approximately four years of delaying diabetes progression.
Cardiovascular disease costs the NHS approximately 7.4 billion pounds annually in England. The cost of a single major adverse cardiovascular event, including the emergency intervention, hospitalisation, and ongoing medication and management, typically exceeds 30,000 pounds in the first year alone, with ongoing costs for secondary prevention medication, cardiac rehabilitation, and management of the functional limitations that a heart attack or stroke frequently produces. The annual cost of a comprehensive cardiovascular prevention programme including the biomarker testing described in this article series, regular exercise, and dietary optimisation is a small fraction of the cost of managing a single preventable event. The challenge is that prevention investment occurs years before the event it prevents, making the return on investment difficult to quantify personally in the way that treating an acute event is perceived.
The Personal Financial Argument for the Longevity MOT
For individuals rather than health systems, the economics of prevention are even more compelling. An adult on the Isle of Man who develops type 2 diabetes at 55 typically faces not only the health consequences but the financial consequences of reduced productivity if still working, potential early retirement forced by health limitations, the cost of medications and monitoring that insurance may or may not cover, and in some cases the cost of care and home modifications as complications progress. An adult who identifies insulin resistance at 48, implements the lifestyle changes that prevent its progression to diabetes, and maintains good metabolic health into their 70s and 80s avoids all of these costs and retains the productivity, independence, and quality of life that represents the largest part of what makes the later decades worth living fully.
Time spent in poor health is not only a financial cost but an opportunity cost: years spent managing chronic disease complications are years not spent with family, pursuing interests, working productively, or living actively. The most conservative estimate of the economic value of good health in later life, expressed as quality-adjusted life years saved by prevention, consistently demonstrates that investment in preventive health assessment and the lifestyle changes it informs produces among the highest returns available from any healthcare investment. The Longevity MOT at Zhen Wellness on the Isle of Man is not a luxury; it is a rational investment in the biological infrastructure that determines the quality of the decades ahead.
What the MOT Finds and What It Costs to Act on
The value of a Longevity MOT is determined not by the assessment itself but by what is done with the information it generates. An MOT that identifies elevated ApoB and early insulin resistance and produces a clear, actionable, evidence-based programme to address both provides value proportional to the disease prevented. An MOT that produces a list of biomarker results without an accompanying strategy for acting on them is significantly less valuable. At Zhen Wellness on the Isle of Man, every Longevity MOT includes a detailed feedback consultation in which the results are explained, their clinical significance is communicated, and a personalised programme addressing the specific findings is developed with the client.
The cost of acting on Longevity MOT findings varies widely depending on what is found and what is recommended. For many clients, the most important interventions are free: walking more, eating less sugar, sleeping an extra hour, doing resistance exercise twice weekly. For others, specific supplements such as vitamin D, omega-3 fatty acids, or creatine are recommended, at modest annual costs. For a smaller proportion with specific findings requiring further investigation, referral to their GP for clinical follow-up is advised, coordinating the preventive medicine findings of the Longevity MOT with the NHS clinical pathway. At Zhen Wellness on the Isle of Man, we aim to ensure that every client leaves the Longevity MOT consultation knowing exactly what they need to do, why it matters, and how to start.
Time Saved by Early Action: Compounding Prevention
Prevention compounds in a way that treatment does not. An adult who begins a resistance training programme at 45, optimises their protein intake, and addresses early insulin resistance at this stage will, by 65, have maintained substantially more muscle mass and better metabolic health than their sedentary, poorly-nourished peer. The health gap between them is not linear: it is compounding, with each year of preserved muscle and metabolic health reducing the rate of subsequent deterioration. The person who invests in their longevity at 45 does not merely delay the same endpoint by 10 years; they enter a qualitatively different biological trajectory that remains good longer, declines more gradually, and preserves independence substantially later into life.
This compounding nature of prevention is the most powerful argument for the Longevity MOT being most valuable in the 40s rather than the 60s. Not because older adults should not have it, but because every year of early action compounds into a larger gap between the preventive investment path and the default path. Adults on the Isle of Man who are in their 40s and reading this are in the most powerful intervention window available for their long-term health. The Longevity MOT at Zhen Wellness provides the biological data and the personalised programme to make the most of it.
- Type 2 diabetes costs 20,000-40,000 per individual in lifetime NHS costs; the Diabetes Prevention Programme recovers this in 4 years
- A single cardiovascular event costs over 30,000 in year one; preventive biomarker programmes cost a fraction of this
- The personal financial and quality-of-life costs of chronic disease exceed the NHS costs
- Quality-adjusted life years analysis consistently shows preventive health investment produces the highest healthcare returns
- Prevention value is determined by what you do with the information: the programme following the MOT matters as much as the assessment
- Most important interventions identified by Longevity MOT are free: sleep, exercise, diet, and stress management
- Prevention compounds: early investment at 45 produces a qualitatively different health trajectory, not just a delayed decline
Sources
- Knowler, W.C., et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393-403.
- Kokkinos, P., et al. (2022). Cardiorespiratory fitness and mortality risk across the spectra of age, race, and sex. JAMA Network Open, 5(5), e2218174.
- Ford, E.S., et al. (2010). Healthy living is the best revenge: findings from the European Prospective Investigation Into Cancer. Archives of Internal Medicine, 170(15), 1355-1362.
- Livingston, G., et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, 396(10248), 413-446.
- Diabetes UK (2023). The cost of diabetes: annual report on the economic impact of diabetes in the United Kingdom.